. In this study, we targeted the vascular endothelium by using a lentivirus construct expressing CYP4A2 under the control of the endothelium-specific promoter VE-cadherin (VECAD-4A2) and examined the effect of long-term CYP4A2 overexpression on blood pressure and kidney function in SD rats. A bolus injection of VECAD-4A2 increased blood pressure (P Ͻ 0.001) by 26, 36, and 30 mmHg 10, 20, and 30 days postinjection, respectively. Arteries from VECAD-4A2-transduced rats produced increased levels of 20-HETE (P Ͻ 0.01), expressed lower levels of endothelial nitric oxide synthase (eNOS) and phosphorylated eNOS (p-eNOS) (P Ͻ 0.05), generated higher levels of superoxide anion, and displayed decreased relaxing responsiveness to acetylcholine (P Ͻ 0.05). Proteinuria increased by twofold in VECAD-4A2-transduced rats compared with controls. Treatment of VECAD-4A2-transduced rats with HET0016, an inhibitor of 20-HETE biosynthesis, not only attenuated the increase in blood pressure (P Ͻ 0.05) but also improved vascular function (acetylcholineinduced relaxations) and reduced plasma creatinine and proteinuria. HET0016 treatment decreased oxidative stress and increased the phosphorylated state of key proteins that regulate endothelial function, including eNOS, AKT, and AMPK. Collectively, these findings demonstrate that augmentation of vascular endothelial 20-HETE levels results in hypertension, endothelial dysfunction, and renal injury, which is offset by HET0016 through a reduction in vascular 20-HETE coupled with a lessening of oxidative stress and the amplification of pAKT, pAMPK, and p-eNOS levels leading to normalization of endothelial responses.
produce 20-hydoxyeicosatetraenoic acid , has been linked to the regulation of vascular and tubular homeostasis and to the development of hypertension in genetic and experimental models of hypertension. This link was originally derived from studies indicating that depletion of CYP4A and inhibition of arachidonic acid -hydroxylation reduced blood pressure in the spontaneously hypertensive rat (SHR) (40) . These and other studies (46, 58) , together with reports that 20-HETE is a vasoconstrictor (8, 29) , suggested that increased vascular 20-HETE synthesis and/or effect contributed to increased blood pressure in SHR and other experimental models of hypertension (1, (32) (33) (34) . These initial findings have been further substantiated with the demonstration that 1) the synthesis of and vascular reactivity to 20-HETE are significantly higher in the SHR than in the normotensive rat (18, 59) , 2) inhibition of vascular 20-HETE synthesis by CYP4A2 antisense oligonucleotides decreases blood pressure (51, 52) , 3) transduction of CYP4A2 increases vascular 20-HETE synthesis and produces hypertension in Sprague-Dawley rats (49) , and 4) administration of a 20-HETE analog prevents the fall in blood pressure in LPS-induced endotoxic shock in rats (48) . In the rat model of androgen-induced hypertension, vascular CYP4A8 expression and 20-HETE synthesis increased (35, 43) and administration of a 20-HETE inhibitor prevented the increase in blood pressure (42) . The male-specific hypertension displayed by the cyp4a14 knockout mouse is thought to be driven by increased cyp4a12 expression (the mouse homolog of CYP4A8) and 20-HETE synthesis (16) . Mice overexpressing human CYP4F2, which has been associated with hypertension (27) , exhibit enhanced 20-HETE production and elevated blood pressure (28) . The prohypertensive mechanism of 20-HETE is primarily derived by its action on the vascular smooth muscle, i.e., inhibition of the large-conductance Ca 2ϩ -activated K ϩ channel (K ca ), leading to vascular smooth muscle cell depolarization and elevation in cystolic Ca 2ϩ concentration (61) . This inhibitory action is believed to underlie the effect of 20-HETE in enhancing responsiveness of arterial vessels to constrictor stimuli, including pressure (21) , oxygen (13, 22) , phenylephrine (59) , and endothelin (37) as well as inhibition of nitric oxide (NO) synthesis (47) . Recent studies from our laboratory (3) and others (5, 9) clearly indicate that in circulatory districts other than the pulmonary, 20-HETE causes endothelial dysfunction and this effect may also contribute to its prohypertensive mechanisms (5, 42, 49) . Collectively, these studies provide substantial evidence that, in the rat, CYP4A genes and the product of their catalytic activity, 20-HETE, are important factors in the development and/or maintenance of hypertension. Recent clinical studies also suggested that such a prohypertensive role for 20-HETE might contribute to human hypertension (53) (54) (55) .
However, this conclusion is not that simple since 20-HETE affects tubular function by inhibiting ion transport (6, 36) . For instance, a deficiency in tubular 20-HETE biosynthesis or action has been linked to salt-sensitive hypertension in animal models (15, 39, 44, 45) and humans (23, 24) . Such duality could be accounted for by the multiplicity of enzymatic sources, their tissue-specific localization, as well as the possibility of tissue-specific "receptor-coupled" signaling pathways for 20-HETE. Therefore, there is a need to develop tissue/cellspecific approaches to modulate 20-HETE levels and actions so as to gain a greater insight into its role in various models of hypertension. To this end, we constructed a lentivirus expressing CYP4A2 cDNA under the control of the endothelialspecific promoter VE-cadherin to evaluate the consequences of increased vascular levels of 20-HETE on blood pressure and vascular and renal function in normotensive Sprague-Dawley rats. We demonstrated that augmentation of vascular endothelial 20-HETE levels by VCAM-CYP4A2 gene targeting resulted in the development of hypertension, endothelial dysfunction, and renal damage. This was diminished by an inhibitor of 20-HETE biosynthesis through a reduction in vascular 20-HETE production coupled with attenuation of oxidative stress followed by amplification of phosphorylated (p)AKT and pAMPK levels and leading to normalization of endothelial responses. These findings demonstrate that vascular overexpression of CYP4A fosters prohypertensive mechanisms via increased production of 20-HETE and that vascular 20-HETE may be an important determinant of endothelial dysfunction and activation.
MATERIALS AND METHODS

Viral vectors and cell cultures.
Lentiviral vectors expressing the CYP4A2 or GFP cDNA under the control of the endothelial specific promoter VE-cadherin (2) were constructed using the LentiMax system (Lentigen, Baltimore, MD). HEK 293 and EA.hy926 cells were used to evaluate transgene expression. Cells seeded in six-well plates at a density of 1 ϫ 10 5 cells/well in 2 ml of DMEM were infected at a multiplicity of infection of 30 with a lentiviral vector carrying the CYP4A2 construct under the control of the endotheliumspecific promoter VE-cadherin (VECAD-4A2). The control vector (VECAD-GFP) carried the green fluorescent protein (GFP) construct. GFP and CYP4A2 protein levels were measured by Western blotting, and GFP expression was also confirmed by vital fluorescence imaging using a confocal laser-scanning microscope (Olympus Fluoview FV300).
Animal experimentation. All experimental protocols were performed following an institutional animal care and use committeeapproved protocol in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Sprague-Dawley rats (9 -10 wk old, 225-250 g body wt) were divided into four groups [control (GFP), CYP4A2, CYP4A2ϩN-hydroxy-N␣-(4-butyl-2-methylphenyl)-formamidine (HET0016), and controlϩHET0016] and were fed a normal chow diet and had access to water ad libitum. Vascular endothelium was targeted by lentiviruses carrying the CYP4A2 or GFP constructs under the control of the endotheliumspecific promoter VE-cadherin (VECAD-4A2 and VECAD-GFP, respectively; Lentigen). Lentiviruses were injected into the left renal artery (200 l of 10 9 TU/ml in saline) and the tail vein (75 l of 10 9 TU/ml in saline) under anesthesia with pentobarbital sodium (65 mg/kg body wt ip). In the groups CYP4A2ϩHET0016 and controlϩHET0016, rats were administered the 20-HETE synthetic inhibitor HET0016 (31) (10 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 ip) for 30 days. Systolic blood pressure was determined before and at 10, 20, and 30 days of treatment by the tail-cuff method. Values within Ϯ10% of their mean blood pressure measurements were obtained. Rats were placed in metabolic cages for 24 h before the termination of the experiment for urine collection. At day 30, rats were euthanized and femoral arteries, renal interlobar arteries, aorta, kidneys, and blood were collected for further study. During euthanization, blood samples were collected in K 3EDTA tubes, which were centrifuged at 2,500 g for 10 min at 4°C to separate the plasma, and stored at Ϫ20°C.
Morphology and immunohistochemistry. Kidneys were harvested and cross sectioned. A portion was fixed in formalin, paraffin embedded, and processed for histology with the standard techniques. Tissue sections were cut at 3-to 4-m thickness. For histopathological evaluation, sections were deparaffined, rehydrated, and stained with hematoxylin-eosin. Sections were also stained with Sirius Red for collagen. Quantitative analysis of Sirius Red data was performed by different investigators unaware of the treatment. Data were collected using sections observed at ϫ40 from 25 randomly chosen fields for each experimental group using a light microscope (Olympus) equipped with an Image analyzer (Image Pro Plus, Milan, Italy). Statistical analysis between different experimental groups was made by ANOVA corrected by Bonferroni's test (significant at P Ͻ 0.05). For immunofluorescence, sections were first deparaffined and rehydrated. Sections were then incubated with 1% BSA (Sigma-Aldrich) for 1 h in a humidified chamber at room temperature and treated overnight at 4°C with the primary antibodies anti-CYP4A2 and CD31, diluted 1:50 in Tris buffer (TBS; 0.1 mol/l, pH 7.4). Consequently, sections were washed in TBS and incubated with fluorescent-conjugated secondary antibodies (Alexa Fluor 488 for CYP4A2; Alexa Fluor 543 for CD31; 1:200) in TBS for 1 h at room temperature. Control reactions were performed in the absence of the primary antibody and in the presence of isotype-matched IgGs. The nuclei were counterstained with 4,6-diamidino-2-phenylindole (Invitrogen) for 8 min at room temperature. Sections were mounted in mounting medium (Dako) and observed with a confocal microscope (LSM 510 META, Zeiss).
Agonist-induced vasorelaxation. The femoral artery was removed and placed in cold Krebs-bicarbonate solution, cleaned of fat and loose connective tissue, and sectioned into 3-mm-long rings. Rings were mounted on wires in myograph chambers (J. P. Trading) for measurement of isometric tension as previously described (20) . Relaxation responses of phenylephrine-constricted arteries to cumulative increments in acetylcholine concentrations (10 Ϫ9 to 10 Ϫ3 M) were studied in the presence of indomethacin (10 mol/l). In all studies, arteries were constricted to 80% of maximal contraction. The response to acetylcholine was also assessed in arteries exposed to N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS; 30 mol/l), a selective CYP4A inhibitor (50) in the absence and presence of 20-HETE (1 mol/l).
Measurement of 20-HETE synthesis. Renal interlobar arteries were incubated in 1 ml oxygenated Krebs buffer (37°C, 60 min) with 1 mmol/l NADPH. Thereafter, an internal standard, [ 2 H6]-20-HETE (500 pg), was added to each sample followed by acidification to pH 4.0 by glacial acetic acid. 20-HETE was extracted with twice the volume of ethyl acetate (3 times), dried under nitrogen, and stored at Ϫ80°C for further analysis. NaOH (1 mol/l, 1 ml) was added to the arteries after extraction for their dissolution and determination of protein concentration (Bio-Rad, Hercules, CA). Identification and quantification of 20-HETE was performed with a Q-trap 3200 linear ion trap quadrupole LC/MS/MS equipped with a Turbo V ion source operated in negative electrospray mode (Applied Biosystems, Foster City, CA). Extracted samples were suspended in 10 l of methanol and injected into the HPLC via an Agilent 1200 standard series autosampler equipped with a thermostat set at 4°C (Agilent Technologies, Santa Clara, CA). The HPLC component consisted of an Agilent 1100 series binary gradient pump equipped with an Agilent Eclipse plus C18 (50 ϫ 4.6 mm, 1.8 m) column (Agilent Technologies). The column was eluted at a flow rate of 0.5 ml/min with 100% mobile phase A [methanol/water/acetic acid (60:40:0.01, vol/vol/vol)] from 0 to 2 min and a gradient increasing to 100% B (100% methanol) at 13 min. Multiple reaction monitoring (MRM) was used with a dwell time of 25 or 50 ms for each compound, with source parameters: ion spray voltage, Ϫ4,500 V; curtain gas, 40 U; ion source gas flow rate 1, 65 U, and 2, 50 U; and temperature of 600°C. Synthetic 20-HETE was used to obtain a standard curve (5-500 pg), and sample peaks were extrapolated with final data presented as nanograms per milligram protein.
Western blot analysis. Frozen kidneys and aorta were pulverized under liquid nitrogen and homogenized in 10 mmol/l potassium phosphate buffer, pH 7.2, containing 25 mmol/l sucrose, 0.1% NP-40, 1 mmol/l EDTA, and a cocktail of proteinase inhibitors. The homogenates were centrifuged at 1,000 g for 15 min, and the supernatant was used for Western blot analysis. Proteins (20 -30 g) were separated by SDS-PAGE at 75 V for 2-3 h at room temperature and then transferred electrophoretically to a nitrocellulose membrane. Membranes were incubated with the following primary and secondary antibodies: goat anti-rat CYP4A1 polyclonal antibody (1:3,000; Daiichi Chemical); mouse anti-EGFP monoclonal antibody (1:5,000; Roche); anti-AMPK, anti-pAMPK, anti-AKT, and anti-pAKT (1:5,000, Cell Signaling Technology); and anti-eNOS, anti-p-eNOS, anti-Inos (1:5,000, Santa Cruz Biotechnology), anti-rabbit anti-goat IgG (1:2,000), and goat anti-mouse IgG (1:1,000). Immunoreactive proteins were detected using the ECL Plus detection system (Amersham Life Sciences) according to the manufacturer's instructions. The anti-rat CYP4A1 polyclonal antibody cross-reacts with all CYP4A isoforms, i.e., CYP4A2, CYP4A3, and CYP4A8 (30) . Anti-␤-actin was used to normalize for loading variations.
Measurement of O 2 Ϫ production. Kidney and aorta homogenates were placed in plastic scintillation minivials containing 5 mol/l lucigenin for the detection of O 2 Ϫ in a final volume of 1 ml of air-equilibrated Krebs solution buffered with 10 mmol/l HEPESNaOH (pH 7.4) as described previously (42) Lucigenin chemilumi- nescence was measured using the LS6000IC liquid scintillation counter (Beckman Instruments, San Diego, CA).
Measurements of plasma creatinine and urinary proteins. Urinary protein excretion was measured using the BCA assay (Pierce, Rockford, IL). Plasma creatinine was measured by ELISA (Cayman, Ann Arbor, MI). The assay was performed according to the manufacturer's instructions.
Statistical analysis. The data are presented as means Ϯ SE. Statistical significance (P Ͻ 0.05) between the experimental groups was determined by the Fisher method of analysis for multiple comparisons. For comparison between treatment groups, the null hypothesis was tested by a single-factor ANOVA for multiple groups or unpaired t-test for two groups.
RESULTS
Endothelial-specific transduction. Assessment of transduction specificity was done using cultured human umbilical vein endothelial cells-derived EA.hy926 cells and kidney-derived HEK cells. As seen in Fig. 1 , Western blotting of GFP protein in HEK and EC cells transduced with the VECAD-GFP clearly indicated endothelial-specific transduction of GFP (Fig. 1A) . Immunohistochemistry of kidneys from VECAM-GFP-and VECAM-CYP4A-treated rats showed colocalization of the endothelial-specific marker CD31 (PECAM) and CYP4A2 or GFP (Fig. 1B) , demonstrating the cell-specific targeting of the viral vectors.
Vascular expression of CYP4A2 and production of 20-HETE. To further evaluate whether increased transduction also increased CYP4A2 function, we measured CYP4A2 protein levels and vascular 20-HETE production. As seen in Fig. 2A , CYP4A2 protein levels were significantly (P Ͻ 0.01) increased in kidney and aorta from rats transduced with VECAD-4A2.
Treatment of VECAD-4A2-transduced rats with the CYP4A-20-HETE inhibitor HET0016 attenuated the increase (P Ͻ 0.05) in CYP4A2 levels. This effect of HET0016 is due to its action as a suicide inhibitor, which causes degradation of the enzyme. It is therefore not surprising to observe a reduction in the expression of CYP4A upon long-term treatment. The increased expression of CYP4A2 in VECAD-4A2-transduced rats was associated with increased production of 20-HETE. As seen in Fig. 2B , 20-HETE production in renal interlobar arteries from VECAD-4A2-transduced rats was twofold higher than in arteries from untreated or HET0016-treated VECAD-GFPtransduced rats (control). Importantly, HET00316 inhibited the increase in 20-HETE synthesis in VECAD-4A2-arteries by 80% to levels not significant from control (Fig. 2B) .
Blood pressure and renal injury. Rats transduced with VECAD-4A2 were hypertensive. Systolic blood pressure increased from 115.5 Ϯ 2.2 to 141.4 Ϯ 2.4 mmHg (P Ͻ 0.01) 10 days after transduction with the VECAD-4A2 lentivirus. At day 30 after transduction with the VECAD-4A2 lentivirus, blood pressure remained at 144.2 Ϯ 3.9 mmHg (Fig. 3A) . The control group (VECAD-GFP-transduced rats) displayed a slight increase in blood pressure from 115.2 Ϯ 1.0 to 119.1 Ϯ 1.6 mmHg during the course of the experiment. Daily treatment of VECAD-4A2-transduced rats with HET0016 prevented the increase in blood pressure (118.1 Ϯ 1.6 and 121.5 Ϯ 3.9 mmHg, 10 and 30 days after transduction, respectively), whereas the same treatment did not significantly change the blood pressure in the control group of VECAD-GFP-transduced rats that were treated with HET0016 (114.0 Ϯ 7.9 mmHg at day 30 after transduction) (Fig. 3A) . Similar patterns were noted for plasma creatinine and proteinuria measured 30 days after transduction. As seen in Fig. 3B , plasma creatinine was markedly increased (3-fold) in VECAD-4A2-transduced rats and significantly (P Ͻ 0.05) decreased by 43% upon treatment with the 20-HETE inhibitor HET0016. Similarly, proteinuria was twofold higher in VECAD-4A2-transduced rats than in control VECAD-GFPtransduced rats. Treatment with HET0016 reduced proteinuria in the VECAD-4A2-transduced rats by 30% (Fig. 3C) .
Kidneys from control VECAD-GFP-transduced rats displayed normal cortical and medullary features (Fig. 4A) . The cortex showed a number of proximal and distal tubules located around the glomerulus. The medulla showed different portions of Henle loops and a number of peritubular capillaries (vasa recta). Both cortex and medulla showed very little collagen, stained by the Sirius Red method, distributed throughout anatomic structures (Fig. 4B) . In contrast, VECAD-4A2-transduced rats showed renal morphological changes with marked histological alterations in the cortex and medulla. The cortical changes consisted of tubular and glomerular injury with dilation of the lumen and Bowman's capsule, respectively (Fig. 4A) . Medullary alterations included disruption of the vasa recta and an increase in inflammatory cells. In addition, Sirius Red staining indicated a marked interstitial fibrosis that was evident around both tubules and glomeruli in the cortex and around the damaged vasa recta in the medulla (Fig. 4, B and C) . The renal damage (both in cortex and medulla) was time dependent and was more evident at day 30. It should be noted that while hypertension in the VECAD-4A2-transduced rats was ameliorated by HET0016 (Fig. 3) , renal injury was not significantly altered. Treatment of VECAD-4A2-transduced rats with HET0016 showed both glomerular and tubular injury (Fig. 4, A-C) .
Vascular function (acetylcholine-mediated vasorelaxation). We have previously shown that 20-HETE uncouples eNOS and that increased vascular synthesis of 20-HETE causes endothelial dysfunction (3, 42) . As seen in Fig. 5A , relaxation to acetylcholine was significantly (P Ͻ 0.05) impaired in femoral arteries of VECAD-4A2-transduced rats, bringing the EC 50 for acetylcholine to 5.75 Ϯ 0.2 ϫ 10 Ϫ5 compared with 2.45 Ϯ 0.3 ϫ 10 Ϫ5 M in arteries from VECAD-GFP-transduced rats (Fig. 5B) . A further demonstration of the contribution of 20-HETE to the impaired acetylcholine-induced vasorelaxation is shown in Fig. 5C . Addition of DDMS, an inhibitor of 20-HETE biosynthesis, reversed the impaired vasorelaxation responses, resulting in an EC 50 of 2.18 Ϯ 0.2 ϫ 10 Ϫ5 M acetylcholine (Fig. 5D ), which was not significantly different from that of the control arteries (Fig. 5B) . The back addition of 20-HETE to the DDMS-treated arteries attenuated the DDMS effect by 55%, increasing the EC 50 for acetylcholine to 3.39 Ϯ 0.1 ϫ 10 Ϫ5 M. Superoxide production. Kidneys and aortas from VECAD-4A2-transduced rats demonstrated a marked increase in the levels of superoxide, suggesting an induction of the oxidative stress response. In the kidney, increased expression of CYP4A2 was associated with an eightfold increase in superoxide production. Treatment of VECAD-4A2-transduced rats with HET0016 reduced superoxide production by 40%, but production still remained significantly (P Ͻ 0.05) higher than in kidneys from control VECAD-GFP-transduced rats (Fig. 6A) . Superoxide levels in aortas from VECAD-4A2-transduced rats were twofold higher than in control aortas (Fig. 6B) . Treatment with HET0016 completely inhibited superoxide production, indicating that 20-HETE is the primary contributor to superoxide production in the aorta.
AKT, AMPK, and eNOS expression. AKT and AMPK are two kinases with key functions in the regulation and activation of eNOS. As seen in Fig. 7, A and B, increased expression of CYP4A2 attenuated the phosphorylation levels of these two kinases in both kidneys and aortas, suggesting that CYP4A2 exerts an inhibitory effect on the activity of these kinases. Furthermore, treatment with HET0016 reversed the effect of CYP4A2 overexpression, suggesting that 20-HETE mediates the inactivation of AKT and AMPK (Fig. 7) . The level of eNOS protein was also affected by 20-HETE. As seen in Fig. 7C , eNOS protein was significantly (P Ͻ 0.05) reduced in kidneys and aortas of VECAD-4A2-transduced rats. Treatment with HET0016 restored the levels of eNOS protein and increased it above the levels measured in control VECAD-GFP-transduced rats, suggesting that 20-HETE exerts an inhibitory influence on eNOS. Similar results were obtained with p-eNOS; levels of p-eNOS were markedly reduced in kidneys and aortas of VECAD-4A2-transduced rats. Treatment with HET0016 re- stored and increased these levels above those of control in VECAD-GFP-transduced rats (Fig. 7D) .
DISCUSSION
The present study demonstrates that targeted overexpression of CYP4A2 in the vasculature leads to endothelial dysfunction, renal injury, and hypertension primarily via increased production of 20-HETE. 20-HETE has multiple actions in the vasculature; it promotes vasoconstriction through inhibition of the BK ca channel and activation of L-type Ca channels in smooth muscle cells (61) and impairs endothelial function through eNOS uncoupling, stimulation of superoxide production, and activation of a proinflammatory program (3, 11, 19) . These effects are considered the prohypertensive mechanisms of 20-HETE and appear to contribute to the hypertension seen in rats transduced with the VECAD-4A2 vector.
We have previously shown that administration of an adenovirus expressing CYP4A2 to normotensive rats and induction of CYP4A-20-HETE synthesis by androgen both resulted in hypertension that was associated with 20-HETE-mediated endothelial dysfunction (49) . Endothelial expression of CYP4A has been reported in the pulmonary circulation (60); however, its endothelial expression in other circulatory districts is nonetheless questionable. Immunohistochemical analysis of CYP4A in arteries from androgen-treated rats suggested endothelial localization (Singh H and Lanaido-Schwartzman M, unpublished observations). These findings together with the demonstration that the endothelium is a major target for 20-HETE actions (3, 19) prompted the current study in which overexpression of CYP4A2 was targeted to the vascular endothelium. This targeted expression is particularly important in view of the welldocumented antihypertensive properties of tubular 20-HETE which stems from its ability to inhibit ion transporters and to promote natriuresis (41) . Therefore, the ability to manipulate 20-HETE synthesis and thereby its levels in a cell-specific manner is essential for elucidating the role of 20-HETE in the control of blood pressure. The targeting was achieved by the selective endothelium-specific promoter VE-cadherin, a transmembrane protein solely expressed at intercellular junctions of all endothelial cell types (25) . The VECAD promoter is widely used to direct endothelial-specific expression of numerous genes (10) . To achieve a longer duration of transgene expression, we used lentiviral vectors (17) . Hence, a bolus intravenous injection of lentiviral constructs expressing CYP4A2 or GFP under the control of the VECAD promoter directed the expression of these genes to the vascular endothelium as assessed by their colocalization with CD31, an endotheliumspecific marker. The vascular expression of both CYP4A2 and GFP was evident 10 and 30 days after transduction. Moreover, 20-HETE levels, the functional output of CYP4A2, remained elevated (ϳ2-fold over control) 30 days after lentivirus administration.
The main finding of this study is that the sustained expression of CYP4A2 and 20-HETE production in the vascular endothelium maintained elevated blood pressure. Systolic blood pressure 10 days after transduction was as high as 30 days after transduction. The fact that HET0016, given daily throughout the experiment, prevented the rise in blood pressure strongly supports the notion that hypertension is mediated by 20-HETE in this animal model. The increase in blood pressure was associated with endothelial dysfunction as evidenced by impaired acetylcholine-induced relaxations, increased superoxide production, decreased levels of p-eNOS/eNOS, and inactivation of the key signaling kinases (AKT, AMPK) regulating eNOS and endothelial function (26) . Each of these parameters has an important contribution to endothelial dysfunction (14) that may underlie the mechanisms by which 20-HETE impacts endothelial and vascular function. These changes were either reversed or mitigated in rats transduced with VECAD-4A2 and treated with HET0016, an inhibitor of 20-HETE biosynthesis. Moreover, the participation of 20-HETE as a key factor in impairing endothelial-dependent relaxation was supported by the fact that addition of DDMS, an inhibitor of 20-HETE biosynthesis, restored relaxation responses to acetylcholine in the VECAD-4A2-transduced arteries. This suggests that the actions of 20-HETE in the endothelium are readily reversible and that a sustained increase in 20-HETE is required to maintain impaired endothelial function and sustain elevated blood pressure. The observation that HET0016 alone increased eNOS and p-eNOS to levels higher than in the control suggests that 20-HETE is actively involved in the regulation of eNOS expression and activity and implicates it as an endogenous regulator of eNOS function.
The increased expression of CYP4A2 and 20-HETE production in the vasculature was accompanied by an increase in renal injury as evidenced by increased proteinuria, plasma creatinine, and morphological changes. Kidneys from VECAD-4A2-transduced rats displayed glomerular and tubular injury, including glomerular sclerosis, lumen dilation, increased interstitial number of inflammatory cells, disruption of the vasa recta, and marked interstitial fibrosis. However, while treatment with HET0016 effectively normalized blood pressure and restored acetylcholine-induced relaxation to that in the control group, it only partially (30 -40%) attenuated proteinuria and plasma creatinine. Moreover, VECAD-4A2-transduced rats treated with HET0016 still displayed renal injury that was not different from that seen in the untreated group, indicating that inhibition of 20-HETE biosynthesis does not lessen, and perhaps worsens, renal injury instigated by increased vascular expression of CYP4A2. The decrease in proteinuria and plasma creatinine following HET0016 treatment could be the consequence of the blood pressure-lowering effect of HET0016.
The dissociation of the effects of HET0016 on blood pressure and renal function is not surprising given that 20-HETE plays a cytoprotective role in the kidney. This renoprotective role is based on 20-HETE-inhibitory actions of ion transport in renal epithelia (7), its natriuretic property (24) , and its ability to prevent the transforming growth factor-␤1-mediated increase in glomerular permeability to albumin (57) . Studies showing that 1) blockade of 20-HETE synthesis with HET0016 exacerbated renal dysfunction following ischemia-reperfusion injury whereas treatment of rats with 20-HETE analogs mitigated renal dysfunction and tubular injury; and 2) increased renal synthesis of 20-HETE in Dahl S rats attenuated the development of hypertension-induced proteinuria and glomerular disease (4, 38, 56) clearly documented the renoprotective capacity of 20-HETE. It is apparent that while our approach for increasing 20-HETE is targeted to the vasculature, the approach to inhibit 20-HETE synthesis is not. It is likely that HET0016 treatment resulted not only in reduction of vascular 20-HETE but also in reduction of renal 20-HETE, which consequently contributed to renal injury. Similar findings were reported by Williams et al. (56) , who showed that chronic treatment of Dahl S rats on a high-salt diet with HET0016 aggravated glomerular injury. The opposing effects of 20-HETE on vascular and tubular function emphasize the need for developing site-directed strategies to control both the synthesis and effect of 20-HETE; it also highlights the extensive studies that are required to elucidate the signaling mechanisms that differentiate these two opposing properties of 20-HETE.
It should be noted that HET0016 has been shown to inhibit the activity of CYP epoxygenases and the activity of cyclooxygenases, although, at concentrations 70-to 100-fold higher than those required to inhibit CYP4A (31) . Nevertheless, we cannot exclude the possibility that such effects could also contribute to the observed renal injury, since both EETs and prostaglandins have renoprotective functions (12) .
In summary, endothelial-specific expression of CYP4A2 resulted in hypertension, endothelial dysfunction, and renal injury that were mediated for the most part by increased levels of 20-HETE. Although inhibition of 20-HETE synthesis normalized blood pressure and restored endothelial function, it exacerbated renal injury. Such effects underscore the multiplicity of the bioactions of 20-HETE and the need to target its synthesis and action in a cell-specific manner. 20-HETE has both pro-and antihypertensive properties, both of which have been associated with human hypertension (23, 24, 27, 55) . The findings in this study provide further evidence that vascular overexpression of CYP4A fosters prohypertensive mechanisms via increased production of 20-HETE and that vascular 20-HETE may be an important determinant of endothelial dysfunction and activation.
